Secondary hyperlipidemia: features of manifestation in various somatic diseases

Close metadata

Recommended articles:

Chronic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medicine. 2025;(1):115-121

Secondary hyperlipidemia is an important risk factor for the formation and development of atherosclerosis in patients with various somatic diseases. According to a number of sources among persons with lipid metabolism disorders up to 30% have secondary hyperlipidemia. The mechanisms of development of lipid metabolism disorders as well as the peculiarities of their manifestations are due to the pathogenesis of the main somatic diseases. Assessment of the risk of developing cardiovascular complications determines the tactics of managing patients with secondary hyperlipidemia. Traditionally, in international recommendations the tactics of managing patients with secondary hyperlipidemia are limited in some patient groups. The review article examines the features of hyperlipidemia and the possibility of its correction in three somatic diseases: nephrotic syndrome, hypothyroidism, non-alcoholic fatty liver disease. In all cases the lipid-lowering therapy is advisable to achieve target lipid levels.

Keywords:

secondary hyperlipidemia

nephrotic syndrome

hypothyroidism

fatty liver disease

Authors:

Mamedov M.N.

National Medical Research Center for Therapy and Preventive Medicine

Karimov A.K.

National Medical Research Centre for Therapy and Preventive Medicine

Received:

30.09.2020

Accepted:

25.11.2020

List of references:

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. https://doi.org/101093/eurheartj/ehw272
Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012;110(6):823-825. https://doi.org/10.1016/j.amjcard.2012.04.062
Elisaf M, Tsimihodimos V. Editorial: secondary dyslipidemias. Open Cardiovasc Med J. 2011;5:22-23. https://doi.org/10.2174/1874192401105010022
Mamedov MN. Treatment of dyslipidemia: from recommendations to clinical practice. M.: Kardioprogress; 2014. (In Russ.).
Bernadette Biondi. Persistent Dyslipidemia in Patients with Hypothyroidism: A Good Marker for Personalized Replacement Therapy? The Journal of Clinical Endocrinology & Metabolism. 2019;104(2):624-627. https://doi.org/10.1210/jc.2018-02302
McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011;21(8):837-843. https://doi.org/10.1089/thy.2010.0298
Delitala AP, Scuteri A, Maioli M, Mangatia P, Vilardi L, Erre GL. Subclinical hypothyroidism and cardiovascular risk factors. Minerva Med. 2019; 110(6):530-545. https://doi.org/10.23736/S0026-4806.19.06292-X
Saavedra A, Rodrigues E, Carvalho D. Dyslipidemia Secondary to Hypothyroidism and Cholestasis. Acta Med Port. 2020;33(3):204-207. https://doi.org/10.20344/amp.9944
Hussain A, Elmahdawi AM, Elzeraidi NE, Nouh F, Algathafi K. The Effects of Dyslipidemia in Subclinical Hypothyroidism. Cureus. 2019;11(11): e6173. https://doi.org/10.7759/cureus.6173
Dey A, Kanneganti V, Das D. A study of the cardiac risk factors emerging out of subclinical hypothyroidism. J Family Med Prim Care. 2019;8(7):2439-2444. https://doi.org/10.4103/jfmpc.jfmpc_348_19
Sigal GA, Tavoni TM, Silva BMO, Kalil Filho R, Brandão LG, Maranhão RC. Effects of Short-Term Hypothyroidism on the Lipid Transfer to High-Density Lipoprotein and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer. Thyroid. 2019;29(1):53-58. https://doi.org/10.1089/thy.2018.0190
Murase T, Takeshita A, Arimoto S. Biphasic dyslipidemia in a patient with painless thyroiditis. J Clin Lipidol. 2018;12(6):1367-1370. https://doi.org/10.1016/j.jacl.2018.09.009
Yu Q, Wang JB. Subclinical Hypothyroidism in PCOS: Impact on Presentation, Insulin Resistance, and Cardiovascular Risk. Biomed Res Int. 2016; 2016:2067087. https://doi.org/10.1155/2016/2067087
Wang C-S, Greenbaum LA. Nephrotic Syndrome. Pediatr Clin North Am. 2019;66(1):73-85.
Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. Am Fam Physician. 2016;93(6):479-485.
Silva-Fernández L, Otón T, Askanase A, Carreira P, López-Longo FJ, Olivé A, Rúa-Figueroa I, Narváez J, Ruiz-Lucea E, Andrés M, Calvo E, Toyos F, Alegre-Sancho JJ, Tomero E, Montilla C, Zea A, Uriarte E, Calvo-Alén J, Marras C, Martínez-Taboada VM, Belmonte-López MA, Rosas J, Raya E, Bonilla G, Freire M, Pego-Reigosa JM, Millán I, Hughes-Morley A, Andreu JL, from the Spanish Society for Rheumatology Systemic Autoimmune Diseases Study Group (EAS-SER) Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. Reumatol Clin. 2019;15(1):34-42.
McCloskey O, Maxwell AP. Diagnosis and Management of Nephrotic Syndrome. Practitioner. 2017;261(1801):11-15.
Piskinpasa S, Agbaht K, Akoglu H, Akyel F, Ozkayar N, Coskun EY, Turgut D, Koc E, Odabas AR, Dede F. Unknown Aspect of the Old Disease: Does Dyslipidemia in Systemic AA Amyloidosis Differ From the Dyslipidemia in Primary Glomerulonephritis? Ren Fail. 2015;37(8):1273-1279.
Vaziri ND. Disorders of Lipid Metabolism in Nephrotic Syndrome: Mechanisms and Consequences. Kidney Int. 2016;90(1):41-52.
Haas ME, Levenson AE, Sun X, Liao W-H, Rutkowski JM, de Ferranti SD, Schumacher VA, Scherer PE, Salant DJ, Biddinger SB. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016;134(1):61-72.
Appel GB, Valeri A, Appel AS, Blum C. The Hyperlipidemia of the Nephrotic Syndrome. Am J Med. 1989;87(5N):45-50.
Grundy SM, Vega GL. Rationale and Management of Hyperlipidemia of the Nephrotic Syndrome. Am J Med. 1989;87(5N):3-11.
Moulin B, Ollier J, Olmer M. Disturbances of Lipid Metabolism During Nephrotic Syndrome: Physiopathology and Treatment. Nephrologie. 1992; 13(5):193-199.
Warwick GL, Packard CJ. Pathogenesis of Lipid Abnormalities in Patients with Nephrotic Syndrome/Proteinuria: Clinical Implications. Miner Electrolyte Metab. 1993;19(3):115-126.
Wheeler DC. Lipid Abnormalities in the Nephrotic Syndrome: The Therapeutic Role of Statins. J Nephrol. 2001;14(Suppl 4):70-75.
Keane WF, St Peter JV, Kasiske BL. Is the Aggressive Management of Hyperlipidemia in Nephrotic Syndrome Mandatory? Kidney Int Suppl. 1992; 38:134-141.
Kaysen GA. Nephrotic Hyperlipidemia: Primary Abnormalities in Both Lipoprotein Catabolism and Synthesis. Miner Electrolyte Metab. 1992;18(2-5): 212-216.
Hutchison FN. Proteinuria, Hyperlipidemia, and the Kidney. Miner Electrolyte Metab. 1993;19(3):127-36.
Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36):6571-6592. https://doi.org/10.3748/wjg.v23.i36.6571
Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol. 2018;30(10):1103-1115. https://doi.org/10.1097/MEG.0000000000001235
Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8(1):35-44. https://doi.org/10.1038/nrgastro.2010.191
Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145-171. https://doi.org/10.1146/annurev-pathol-121808-102132
Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. Nutrients. 2013;5(5):1544-1560. https://doi.org/10.3390/nu5051544
Solano-Silva M, Bazán-de Santillana I, Soto-Rodríguez I, Bautista-Piña C, Alexander-Aguilera A. Tissue Changes in the Development of Fatty Liver by Chronic Ingestion of Sucrose Associated with Obesity and Dyslipidemia in Rats. Int J Vitam Nutr Res. 2018;88(3-4):117-125. https://doi.org/10.1024/0300-9831/a000247
Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016;65(8):1109-1123. https://doi.org/10.1016/j.metabol.2016.05.003
Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014;15(4):493-503. https://doi.org/10.1517/14656566.2014.876992
Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes. 2019;26(2):103-108. https://doi.org/10.1097/MED.0000000000000464
Ray G, Agarwala T. A study of metabolic parameters in non diabetic patients with non alcoholic fatty liver disease — importance of dyslipidemia. Arq Gastroenterol. 2019;56(3):270-275. https://doi.org/10.1590/S0004-2803.201900000-51
Nemes K, Åberg F. Interpreting lipoproteins in nonalcoholic fatty liver disease. Curr Opin Lipidol. 2017;28(4):355-360. https://doi.org/10.1097/MOL.0000000000000427
Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22-29. https://doi.org/10.1055/s-0032-1306423
Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(7):1077-1084. https://doi.org/10.1016/j.cgh.2013.08.014
Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O’Donnell CJ, Fox CS. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51(6):1979-1987. https://doi.org/10.1002/hep.23593
Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019;34(8):1390-1395. https://doi.org/10.1111/jgh.14595

Close metadata